Switching or Stopping HIV Treatment

The Latest

This Week in HIV Research: Additional Nuance on Pregnancy and Antiretrovirals

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

By Barbara Jungwirth and Myles Helfand

De-Simplifying Single-Tablet Regimens for HIV Treatment

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

This Week in HIV Research: A Long-Acting Popularity Contest

The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.

By Barbara Jungwirth and Myles Helfand

Dolutegravir: Need to Consider All Pros and Cons Before Switching in Pregnancy

A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.

By Polly Clayden for HIV i-Base

Advances in Two-Drug Antiretroviral Regimens

Given the potency of new antiretroviral therapy (ART) and the life-long duration that people living with HIV/AIDS will require ART, there is a continued interest in two-drug ART regimens.

By Amesika N. Nyaku, M.D., M.S. for American Academy of HIV Medicine

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses

Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.

By Simon Collins for HIV i-Base

Assessing Antiretroviral Therapy Interruptions in HIV Cure Research

During a clinical trial of the broadly neutralizing antibody VRC01, study results offered reassurance that treatment interruption had no long-term negative effects for participants -- but there are some possible safety concerns that the data does not...

By Richard Jefferys for Treatment Action Group

NIH Study Supports Use of Short-Term HIV Treatment Interruption in Clinical Trials

The findings may aid the design of clinical trials to assess strategies to control HIV without drugs.

By National Institues of Health

Could We Safely Reduce the Frequency of Treatments for HIV-Positive People?

A major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

By Caroline Petit for The Conversation

A Better Second Chance: A Top HIV Clinical Development of 2017

Deciding what to do after the failure of a first-line regimen has long entailed a bit of head-scratching. Aside from the investigation into what went wrong (e.g., adherence), there is the matter of selecting a salvage regimen that can suppress virus ...

By David Alain Wohl, M.D.